Page contents Key factsDecisionKey facts Active Substance Raludotatug deruxtecan Therapeutic area Neoplasms benign, malignant and unspecified (incl cysts and polyps) Decision number P/0100/2024 PIP number EMEA-003569-PIP01-23 Pharmaceutical form(s) Powder for concentrate for solution for infusion Condition(s) / indication(s) Treatment of fallopian tube cancerTreatment of ovarian cancerTreatment of primary peritoneal cancer Route(s) of administration Intravenous use Contact for public enquiries Daiichi Sankyo Europe GmbHE-mail: service@daiichi-sankyo.euTel.: +49 8978080 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 05/04/2025DecisionP/0100/2024: EMA decision of 5 April 2024 on the granting of a product-specific waiver for raludotatug deruxtecan (EMEA-003569-PIP01-23)AdoptedReference Number: EMA/139618/2024 English (EN) (206.46 KB - PDF)First published: 06/06/2025ViewShare this page